Cyclacel pharmaceuticals to present new clinical data at 2024 asco annual meeting highlighting fadraciclib's potential as a precision medicine for cancer

- new clinical, pk and pd data from novel cdk2/9 inhibitor fadraciclib monotherapy studies support ongoing development program in patients with solid tumors and lymphoma -

CYCC Ratings Summary

CYCC Quant Ranking